Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 12/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 2/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000089 | 0.79 | ACLY (0.72) | ACLYKMT2AGAAMCL1 | |
| SCHEMBL21999679 | 0.78 | ACLY (0.71) | ACLYCCKBRMCL1 | |
| SCHEMBL9997760 | 0.78 | ACLY (0.64) | ACLYPOLBGFERKMT2AALDH1A1 | |
| SCHEMBL21999860 | 0.77 | ACLY (0.69) | ACLYMCL1 | |
| SCHEMBL22000007 | 0.76 | ACLY (0.61) | ACLYMCL1 | |
| SCHEMBL22000566 | 0.76 | ACLY (0.61) | ACLYMCL1 | |
| SCHEMBL5244010 | 0.75 | ACLY (0.60) | ACLYPOLBGFERKMT2AALDH1A1 | |
| SCHEMBL21931063 | 0.74 | ACLY (1.00) | ACLYMCL1 | |
| SCHEMBL21930839 | 0.74 | ACLY (1.00) | ACLY | |
| SCHEMBL22000002 | 0.74 | ACLY (0.81) | ACLYKMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885POLB 794/4885GFER 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.